ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,641 to 1,660 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Cangrelor vs Clopidogrel: Incidence of Stent Thrombosis15 of 2,647

28 of 2,629

-0.5 points

-1.0 to -0.0

5,276NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Cangrelor vs Clopidogrel: Incidence of All-cause Mortality, MI, or IDR227 of 2,647

249 of 2,629

-0.9 points

-2.4 to 0.7

5,276NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Cangrelor vs Clopidogrel: Incidence of IDR37 of 2,647

46 of 2,629

-0.4 points

-1.0 to 0.3

5,276NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Genotype-Guided Therapy vs Conventional Therapy: Occurrence of the a Major Adverse Cardiovascular Event262 of 2,641

269 of 2,635

-0.3 points

-1.9 to 1.3

5,276NCT01742117

Tailored Antiplatelet Therapy Following PCI

Genotype-Guided Therapy vs Conventional Therapy: Thrombolysis in Myocardial Infarction Major or Minor Bleeding54 of 2,641

53 of 2,635

0.0 points

-0.7 to 0.8

5,276NCT01742117

Tailored Antiplatelet Therapy Following PCI

Genotype-Guided Therapy vs Conventional Therapy: deaths from any cause95 of 2,641

98 of 2,635

-0.1 points

-1.1 to 0.9

5,276NCT01742117

Tailored Antiplatelet Therapy Following PCI

Experimental Group vs Control Group: deaths from any cause23 of 476

209 of 4,793

0.5 points

-1.2 to 2.8

5,269NCT02694185

Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications

High Dose Influenza Vaccine vs Standard Dose Influenza Vaccine: deaths from any cause223 of 2,630

222 of 2,630

0.0 points

-1.5 to 1.5

5,260NCT02787044

INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure

Cangrelor vs Clopidogrel: Incidence of All-cause Mortality94 of 2,628

113 of 2,618

-0.7 points

-1.8 to 0.3

5,246NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

RSV MAT Group - Infant vs Placebo Group - Infant: Number of Infant Participants With at Least One MAE From Birth to Day 366 Post-birth2,706 of 3,494

1,330 of 1,741

1.1 points

-1.3 to 3.5

5,235NCT04605159

A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers

RSV MAT Group - Infant vs Placebo Group - Infant: Number of Infant Participants With at Least One Serious Adverse Event (SAE) From Birth to Day 181 Post-birth640 of 3,494

323 of 1,741

-0.2 points

-2.5 to 2.0

5,235NCT04605159

A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers

RSV MAT Group - Infant vs Placebo Group - Infant: Number of Infant Participants With at Least One Adverse Event (AE) Leading to Study Withdrawal From Birth to Day 181 Post-birth19 of 3,494

4 of 1,741

0.3 points

-0.1 to 0.6

5,235NCT04605159

A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers

RSV MAT Group - Infant vs Placebo Group - Infant: Number of Infant Participants With at Least One AE Leading to Study Withdrawal From Birth to Day 366 Post-birth21 of 3,494

4 of 1,741

0.4 points

-0.0 to 0.7

5,235NCT04605159

A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers

RSV MAT Group - Infant vs Placebo Group - Infant: Number of Infant Participants With at Least One SAE From Birth to Day 366 Post-birth731 of 3,494

371 of 1,741

-0.4 points

-2.8 to 1.9

5,235NCT04605159

A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers

RSV MAT Group - Infant vs Placebo Group - Infant: Number of Infant Participants With at Least One Medically Attended AE (MAE) From Birth to Day 181 Post-birth2,321 of 3,494

1,135 of 1,741

1.2 points

-1.5 to 4.0

5,235NCT04605159

A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers

Telmisartan (TRANSCEND) vs Placebo (TRANSCEND): TRANSCEND. Cognitive Decline230 of 2,642

192 of 2,589

1.3 points

-0.2 to 2.8

5,231NCT00153101

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

High Dose Influenza Vaccine vs Standard Dose Influenza Vaccine: serious adverse events2 of 2,606

4 of 2,604

-0.1 points

-0.3 to 0.1

5,210NCT02787044

INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure

AndroGel 1.62% vs Placebo: Time From Randomization to First Clinical Fracture: Number and Percentage of Participants With an Event91 of 2,601

64 of 2,603

1.0 points

0.1 to 2.0

5,204NCT03518034

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

CT Colonography vs Colonoscopy: serious adverse events0 of 2,600

1 of 2,600

-0.0 points

-0.2 to 0.1

5,200NCT00084929

The National CT Colonography Trial

AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Heart Failure55 of 2,596

50 of 2,602

0.2 points

-0.6 to 1.0

5,198NCT03518034

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=83

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00385138-48978c40",
        "title": "Cangrelor vs Clopidogrel: Incidence of Stent Thrombosis",
        "summary": "15 of 2647 against 28 of 2629; risk difference -0.5 points, 95% interval -1.0 to -0.0; NCT00385138, Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.",
        "record": "/library/comparisons/NCT00385138-48978c40",
        "nct_id": "NCT00385138",
        "kind": "outcome",
        "participants": 5276,
        "risk_difference": {
          "value": -0.004983644833289097,
          "lower": -0.010185167602418293,
          "upper": -0.00007293653237660808
        },
        "group_1": "15 of 2,647",
        "group_2": "28 of 2,629",
        "difference": "-0.5 points",
        "interval": "-1.0 to -0.0",
        "trial_title": "Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition."
      },
      {
        "id": "NCT00385138-4abdff99",
        "title": "Cangrelor vs Clopidogrel: Incidence of All-cause Mortality, MI, or IDR",
        "summary": "227 of 2647 against 249 of 2629; risk difference -0.9 points, 95% interval -2.4 to 0.7; NCT00385138, Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.",
        "record": "/library/comparisons/NCT00385138-4abdff99",
        "nct_id": "NCT00385138",
        "kind": "outcome",
        "participants": 5276,
        "risk_difference": {
          "value": -0.00895535728527369,
          "lower": -0.02446565528418624,
          "upper": 0.006527260042186204
        },
        "group_1": "227 of 2,647",
        "group_2": "249 of 2,629",
        "difference": "-0.9 points",
        "interval": "-2.4 to 0.7",
        "trial_title": "Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition."
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=84",
  "request_id": "ybFa20mjjb5UMELi"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?